Literature DB >> 1500268

Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer.

K G Louie1, T C Hamilton, R H Shoemaker, R C Young, R F Ozols.   

Abstract

Five compounds which were identified as potential new anticancer drugs in in vitro screening with the human tumor colony forming assay were selected for further evaluation using in vitro and in vivo models of human ovarian cancer. Three of five compounds were found to inhibit in vitro colony formation of ovarian cancer cell lines derived from both untreated and combination chemotherapy refractory patients. One compound was also found to prolong survival in a human ovarian carcinoma xenograft model system. This compound, chloroquinoxaline sulfonamide, was selected for development and has shown preliminary indication of activity in phase I clinical testing.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500268     DOI: 10.1007/bf00873120

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  12 in total

Review 1.  Development of human tumor cell line panels for use in disease-oriented drug screening.

Authors:  R H Shoemaker; A Monks; M C Alley; D A Scudiero; D L Fine; T L McLemore; B J Abbott; K D Paull; J G Mayo; M R Boyd
Journal:  Prog Clin Biol Res       Date:  1988

2.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

3.  New approaches to antitumor drug screening: the human tumor colony-forming assay.

Authors:  R H Shoemaker
Journal:  Cancer Treat Rep       Date:  1986-01

Review 4.  Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.

Authors:  T C Hamilton; R C Young; R F Ozols
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

5.  The National Cancer Chemotherapy Program.

Authors:  E Frei
Journal:  Science       Date:  1982-08-13       Impact factor: 47.728

6.  The preclinical new drug research program of the National Cancer Institute.

Authors:  J S Driscoll
Journal:  Cancer Treat Rep       Date:  1984-01

7.  Application of a human tumor colony-forming assay to new drug screening.

Authors:  R H Shoemaker; M K Wolpert-DeFilippes; D H Kern; M M Lieber; R W Makuch; N R Melnick; W T Miller; S E Salmon; R M Simon; J M Venditti
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

8.  Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.

Authors:  K G Louie; B C Behrens; T J Kinsella; T C Hamilton; K R Grotzinger; W M McKoy; M A Winker; R F Ozols
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

9.  Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.

Authors:  T C Hamilton; R C Young; K G Louie; B C Behrens; W M McKoy; K R Grotzinger; R F Ozols
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

10.  Metabolic stability of experimental chemotherapeutic agents in hepatocyte:tumor cell co-cultures.

Authors:  P L Appel; M C Alley; M M Lieber; R Shoemaker; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more
  1 in total

1.  In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo.

Authors:  K Yao; J A Gietema; S Shida; M Selvakumaran; X Fonrose; N B Haas; J Testa; P J O'Dwyer
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.